PATENTSCOPE will be unavailable a few hours for maintenance reason on Tuesday 19.11.2019 at 4:00 PM CET
Search International and National Patent Collections
Some content of this application is unavailable at the moment.
If this situation persists, please contact us atFeedback&Contact
1. (EP3413880) NANOCARRIER COLOADED WITH AN INHIBITOR OF EXOCYTOSIS AND AN ACTIVE INGREDIENT

Office : European Patent Office
Application Number: 17714275 Application Date: 10.02.2017
Publication Number: 3413880 Publication Date: 19.12.2018
Publication Kind : A1
Designated States: AL, AT, BA, BE, BG, CH, CY, CZ, DE, DK, EE, ES, FI, FR, GB, GR, HR, HU, IE, IS, IT, LI, LT, LU, LV, MC, ME, MK, MT, NL, NO, PL, PT, RO, RS, SE, SI, SK, SM, TR
Prior PCT appl.: Application Number:IB2017050754 ; Publication Number: Click to see the data
IPC:
A61K 9/51
A61K 9/00
A HUMAN NECESSITIES
61
MEDICAL OR VETERINARY SCIENCE; HYGIENE
K
PREPARATIONS FOR MEDICAL, DENTAL, OR TOILET PURPOSES
9
Medicinal preparations characterised by special physical form
48
Preparations in capsules, e.g. of gelatin, of chocolate
50
Microcapsules
51
Nanocapsules
A HUMAN NECESSITIES
61
MEDICAL OR VETERINARY SCIENCE; HYGIENE
K
PREPARATIONS FOR MEDICAL, DENTAL, OR TOILET PURPOSES
9
Medicinal preparations characterised by special physical form
CPC:
A61K 9/5115
A61K 9/0019
Applicants: FONDAZIONE ST ITALIANO DI TECNOLOGIA
Inventors: CORVAGLIA STEFANIA
POMPA PIER PAOLO
Priority Data: 2017050754 10.02.2017 IB
UB20160651 11.02.2016 IT
Title: (DE) MIT EINEM INHIBITOR VON EXOZYTOSE UND EINEM WIRKSTOFF CO-BELADENER NANOTRÄGER
(EN) NANOCARRIER COLOADED WITH AN INHIBITOR OF EXOCYTOSIS AND AN ACTIVE INGREDIENT
(FR) NANOSUPPORT CHARGÉ À LA FOIS D'UN INHIBITEUR DE L'EXOCYTOSE ET D'UN PRINCIPE ACTIF
Abstract:
(EN) A nanocarrier is described loaded with at least one inhibitor of exocytosis and at least one active ingredient. Said nanocarrier is used for medical use, in particular in the treatment of a tumour.
(FR) L'invention concerne un nanosupport chargé d'au moins un inhibiteur de l'exocytose et d'au moins un principe actif. Ledit nanosupport est utilisé à des fins médicales, en particulier dans le cadre du traitement d'une tumeur. Figure principale : figure 2
Also published as:
WO/2017/137949